ERTAN ORUÇ, Adem KARA, İSMAİL CAN, Ali KARADENİZ, Nejdet ŞİMŞEK

Caspase-3 and cd68 ımmunoreactivity in lymphoid tissues and haematology of rats exposed to cisplatin and l-carnitine

Bu çalışmada sisplatin (CDDP) toksikasyonuna maruz kalmış ve dietlerine L-carnitine ilave edilmiş ratların lenfoid dokularında Caspase-3 ve CD68 aktivitesinin belirlenmesi ve elde edilen sonuçların hematolojik bulgularla karşılaştırılması amaçlanmıştır. Bu amaçla kontrol grubunu oluşturan ratlara tek doz peritoniçi (i.p.) izotonik salin, L-car grubuna tek doz 500 mg/kg (i.p.) L-carnitine, CDDP grubuna tek doz 7 mg/kg (i.p.) CDDP, ve son olarak CDDP + L-car grubuna 10 gün boyunca tek doz 500 mg/kg (i.p.) L-carnitine ve akabinde tek doz 7 mg/kg (i.p.) CDDP uygulandı. Deneme sonrası elde edilen bulgular doğrultusunda, kontrol grubu ile kıyaslandığında CDDP grubunda lenfosit oranında artış varken toplam WBC oranı azalmıştı. Diğer tarafdan nötrofil lökosit ve monosit oranlarında da CDDP grubunda kontrol grubuna oranla azalma görüldü. Bu bulguların aksine L-car+CDDP grubunda toplam WBC, nötrofil lökosit ve lenfosit miktarında CDDP grubuna oranla artış tespit edildi. Caspase-3 immunopozitifliği lenfoid dokularda değişen derecelerde tespit edilirken, diyete L-carnitine ilavesi ile sisplatinin apoptotik etkisinde azalma görüldü. CD68 pozitiflik oranı kontrol, L-car ve L-car + CDDP gruplarında birbirine yakın ve orta şiddette bulunurken CDDP grubunda CD68 pozitiflik oranı daha düşük düzeyde tespit edildi. Elde edilen bulgular ışığında, sisplatinin lenfoid dokularda apoptozisi arttırdığı, makrofaj aktivitesini ise azalttığı, her iki etkinin özellikle lenf düğümünde daha belirgin, timusda ise daha az etkide olduğu sonucuna varıldı.

Anahtar Kelimeler:

hematoloji, boyun altı bezi, sıçan, karnitin, enzim aktivitesi, lenf düğümleri

Sisplatin ve l-karnitin’e maruz kalmış ratların lenfoid dokularında caspase-3 ve cd68 ımmunoreaktivitesi ve hematolojisi

This study was performed to determine caspase-3 and CD68 activities in lymphoid tissues of rats exposed to Cisplatin (CDDP) induced toxicity and L-carnitine (L-Car) protection. Group control was received single-dose intraperitoneal (i.p.) 1 ml isotonic saline, Group L-Car received single-dose injections of L-carnitine 500 mg/kg bw. i.p., Group CDDP received a single-dose injection of CDDP 7 mg/kg bw i.p. all at once, Group L-Car + CDDP received single doses of L-carnitine 500 mg/kg bw i.p. for 10 consecutive days and following a single-dose i.p. injection of CDDP 7 mg/kg bw i.p. When compared to the control group, the numbers of total WBC were decreased while a relative increase in lymphocyte percentages was observed in the CDDP-treated group. On the other hand, relative decreases in neutrophil and monocyte percentages were observed in the CDDP-treated group compared to control group. Conversely, L-Car treatment with CDDP injections caused significantly increased the number of total WBC. Caspase-3 immunopositivity was found in varying degree in lymphoid tissues. L-carnitine supplementation to diet decreased apoptotic effect of cisplatin. CD68 positive cells were found similar in control and L-Car groups. While CD68 positivity was found in low degree in CDDP group, it was moderate in L-Car + CDDP group. It is concluded that cisplatin increases apoptosis and decrease macrophage activity in lymphoid tissues. This both effects were found especially in lymph node in high degree and thymus in low degree.

Keywords:

haematology, thymus gland, rats, carnitine, enzyme activity, lymph nodes,

PDF

___

1. Ries FF, Klastersky JJ: Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis, 8, 368-379, 1986.
2. Bolaman Z, Köseoğlu MH, Demir S, Kadıköylü G, Barutca S, Atalay H, Aslan D: α-tokoferolün sıçan böbreğinde sisplatinin yol açtığı lipid peroksidasyonuna etkisi. Turk J Hematol, 20, 35-38, 1986.
3. Fuertesa MA, Castillab J, Alonsoa C, Perez JM: Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem, 10, 257-266, 2003
4. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-7279, 2003.
5. Karimi G, Ramezani M, Tahoonian Z: Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Compl Alt, 2, 383-386, 2005.
6. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transpl, 21, 2096-2105, 2006.
7. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z: Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol, 73, 1499-510, 2007.
8. Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jee KY, Sung MJ, Park SK, Kim W: Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transpl, 24, 3012-3020, 2009.
9. Yapar K, Cavusoglu K, Oruc E, Yalcin E: Protective effect of royal jelly and green tea extracts effect against cisplatin-induced nephrotoxicity in mice: A comparative study. J Med Food, 12, 1136-1142, 2009.
10. Pratibha R, Sameer R, Rataboli PV, Bhiwgade DA, Dhume CY: Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur J Pharmacol, 532, 290-293, 2006.
11. Miyamato Y, Shimada K, Sakaguchi Y, Miyamato M: Cisplatin (CCDP)-induced acute toxicity in an experimental model of hepatic fibrosis. J Toxicol Sci, 32, 311-319, 2003.
12. Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, Kisa F, Emre H, Turkeli M: Royal Jelly modulates oxidative stress and apoptosis in liver and kidneys of rats Treated with Cisplatin. Oxid Med Cell Longev, DOI:101155/2011/981793, 2011.
13. Wylile AH: Apoptosis: an overview. Brit Med Bul, 53, 451-467, 1997.
14. Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell, 91, 443-446, 1997.
15. Zhan YB, Water VD, Wang Y, Stevens JL: The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene, 18, 6505-6512, 1999.
16. Holness CL, Da Silva RP, Fawcett J, Gordon S, Simmons DL: Macrosialin a mouse macrophage-restricted glycoprotein is a member of the lamp/lgp family. J Biol Chem, 268, 9661-9666, 1993.
17. Da Silva RP and Gordon S: Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68) a macrophage-specific endosomal protein. Biochem J, 338, 687-694, 1999.
18. Moore KJ, Freeman MW: Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol, 26, 1702-1711, 2006.
19. Kelly GS: L-carnitine: Therapeutic applications of a conditionally- essential amino acid. Altern Med Rev, 3, 345-360, 1998.
20. Brass EM: Supplemental carnitine and exercise. Am J Clin Nutr, 72, 618-623, 2000.
21. Atessahin A, Sahna E, Turk G, Ceribasi AO, Yılmaz S, Yuce A, Bulmus O: Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res, 41, 21-27, 2006.
22. Gaedeke JL, Fels M, Bokemeyer C, Mengs U, Stolte H, Lentzen H: Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transpl, 11, 55-62, 1996.
23. De Martins BS, Pires Bianchi MDL: Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res, 44, 317-320, 2002.
24. Yuce A, Atessahin A, Ceribasi AO, Aksakal M: Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol, 101, 345-349, 2007.
25. Al-Majed AA: Carnitine deficiency provokes cisplatin-ınduced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol, 100, 145-150, 2007.
26. Schalm W: Veterinary Hematology, 2nd ed. pp. 47-123, Lea and Febiger, Philadelphia, 1965.
27. Wetzel CC, Berberich SJ: p53 binds to cisplatin- damaged DNA. Biochim Biophys Acta, 1517, 392-397, 2001.
28. Cummings BS, Schnellmann RG: Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther, 302, 8-17, 2002.
29. Lieber J, Kirchner B, Eicher C: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer, 55, 1089-1095, 2010.
30. Safirstein R, Miller P, Guttenplan JB: Uptake and metabolism of cisplatin by rat kidney. Kidney Int, 25, 753-758, 1984.
31. Fritz IB, Martelli EA: Sites of action of carnitine and its derivatives on the cardiovascular system: Interactions with membranes. Trends Pharmacol Sci, 14, 355-360, 1993.
32. Zwelling LA, Michaels S, Schwartz H, Dobson PP, Kohn KW: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res, 41, 640-649, 1981.
33. Nowrousian MR, Schmidt CG: Effects of cisplatin on different haemopoietic progenitor cells in mice. Br J Cancer, 46, 397-402, 1982.
34. Evans RG,Wheatley C, Engel C, Nielsen J, Ciborowski LJ: Modification of the bone marrow toxicity of cis-diamminedichloroplatinum (II) in mice by diethyldithiocarbamate. Cancer Res, 44, 3686-3690, 1984.
35. Das B, Yeger H, Baruchel H, Freedman MH, Koren G, Baruchel S: In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity: Implications in cancer chemotherapy. Eur J Cancer, 39, 2556-2565, 2003.
36. Neuwel EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL: Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther, 309, 594-599, 2004.
37. Gandara DR, Perez EA, Weibe V, De Gregorio MW: Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Semin Oncol, 18, 49-55, 1991.
38. Muggia FM: Cytoprotection: concepts and challenges. Support Care Cancer, 2, 377-379.
39. De Simone CM, Ferrari A, Lozzi D, Meli D, Sorice RF: Vitamins and immunity: II Influence of Lcarnitine on the immune system. Acta Vitaminol Enzymol, 4, 135-140, 1982.
40. Karadeniz A, Simsek N, Cakir H: Haematological effects of dietary L-carnitine supplementation in broiler chickens. Rev Med Vet (Toulouse), 159, 437-443, 2008.
41. Simsek N, Karadeniz A, Bayraktaroğlu AG: Ratlarda periferal jan hücreleri üzerine L-karnitin arı sütü ve nar çekirdeğinin etkileri. Kafkas Univ Vet Fak Derg, 15 (1): 63-69, 2009.
42. Deufel T: Determination of L-carnitine in biological fluids and tissues. J Clin Chem Clin Biochem, 28, 307-311, 1990.
43. Monti D, Cossarizza A, Troiano L, Arrigoni-Martelli E, Franceschi C: Immunomodulatory properties of L acetylcarnitine on lymphocytes from young and old humans In, De Simone C, Martelli EA (Eds): Stress Immunity and Ageing. A Role for L-Acetylcarnitine. pp. 83-96, Elsevier, Amesterdam, 1989.
44. Famularo G, De Simone C, Tzantzoglou S, Trinchieri V: Apotosis anti-apoptotic compounds and TNF-alpha release. Immunol Today, 15, 495-496, 1994.
45. Abd-Allah AR, Al-Majed AA, Al-Yahya AA, Fouda SI, Al-Shabana OA: L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol, 79, 406-413, 2005.
46. Sener G, Eksioglu E, Demiralp M, Cetiner F, Ercan S, Sirvancı N, Gedik B, Yegen C: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol, 22, 47-60, 2006.
47. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S: Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised double-blind placebocontrolled study. Eur J Cancer, 40, 1713-1723, 2004.
48. Ghosh D, Bose A, Haque E, Baral R: Neem (Azadirachta Indica) leaf preparation prevents leukocyte apoptosis mediated by cisplatin plus 5-fluorouracil treatment in swiss mice. Chemotherapy, 55, 137-144, 2009.
49. Ghosh D, Bose A, Haque E, Baral RN: Pretreatment with neem (Azadirachta indica) leaf preparation in Swiss mice diminishes leukopenia and enhances anti-tumor activity of cyclophosphamide. Phytother Res, 20, 814-818, 2006.
50. Das B, Yeger H, Baruchel S: Squalene protects mice bone marrow hematopoietic and mesenchymal stem cells against high-dose cisplatin in vivo by restoring antioxidant balance: Implications in cancer chemo-therapy. Proc Amer Assoc Cancer Res, 47, Abstract nr 30, 2006.
51. Perez-CruI I, Carcamo JM, Golde DW: Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells. Blood, 102, 336-343, 2003.